Sarah Cannon Research Institute
Marilyn (Holt) Hammer, PhD, is a personalized medicine scientist at Sarah Cannon Research Institute, specializing in the review of patient molecular profiling for targeted therapy and clinical trial options. Previously, as a staff scientist at Vanderbilt University Medical Center, Marilyn curated information from electronic health records and clinical trial documents to support clinical studies and decision-making. During tenure as a graduate research assistant at Vanderbilt University, Marilyn focused on biochemical and biophysical studies of human DNA primase and also served as a graduate writing consultant. Early experience includes teaching assistance at Houghton College and undergraduate research at Vanderbilt University. Marilyn obtained a PhD in Chemical and Physical Biology from Vanderbilt University and holds a BS in Chemistry and Biology from Houghton University.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.